Skip to Content Facebook Feature Image

TGI Fridays™ Signs Development Agreement to Fuel Pakistan Growth

Business

TGI Fridays™ Signs Development Agreement to Fuel Pakistan Growth
Business

Business

TGI Fridays™ Signs Development Agreement to Fuel Pakistan Growth

2026-09-23 21:00 Last Updated At:22:25

Plans include scaling to 15 restaurants as TGI Fridays continues to expand its footprint across South Asia and the Middle East under its 1-2-3 Strategic Vision.

DALLAS, Sept. 23, 2026 /PRNewswire/ -- TGI Fridays™ today announced a landmark development agreement with Meerab Hospitality, marking an exciting chapter for the brand in Pakistan and further accelerating its growth across South Asia. Following the brand's recent development agreement in the Maldives, the partnership builds on growing momentum across the region and reinforces TGI Fridays' strategy of expanding its global footprint through strategic, long-term franchise partnerships.

The agreement marks an important milestone in TGI Fridays' continued international expansion and further strengthens the brand's presence across South Asia and the Middle East, as it accelerates toward its 1-2-3 Strategic Vision of 1,000+ restaurants and $2 billion in annual revenue by 2030.

With more than 240 million people and a median age of just 21, Pakistan offers TGI Fridays a compelling combination of scale, youth and long-term growth potential. Rapid urbanization, continued investment in malls and mixed-use destinations, and an evolving dining culture are creating new opportunities for international restaurant brands as consumers increasingly seek distinctive, experience-led dining. Through its partnership with Meerab Hospitality, TGI Fridays is positioned to capture that opportunity with a brand guests already recognize, bringing its signature combination of bold American flavors, legendary mocktails, high-energy atmosphere and unmistakable Fridays hospitality to one of South Asia's most dynamic consumer markets.

Meerab Hospitality brings deep regional expertise and operating strength to the partnership. As the franchise and development arm of Meerab Properties, the company combines a two-decade track record across the Middle East, South Asia and Central Asia with extensive international hospitality experience. Together, TGI Fridays and Meerab Hospitality are well positioned to capture Pakistan's growing appetite for international dining experiences, while creating new employment opportunities, investing in local hospitality talent and bringing the unmistakable Fridays spirit to a new generation of guests.

"We don't enter a market like Pakistan because it's on a list — we enter it because the fundamentals are right and the partner is right," said Phil Broad, Global President, TGI Fridays. "Pakistan has one of the youngest populations anywhere in the world and a retail landscape that's evolving fast. Meerab Hospitality understands that better than an outside operator could, and their hospitality background means they know how to run a room, not just build one. That's the combination we look for.

What makes Pakistan particularly exciting is the energy of the market and the generation coming through. They're connected, curious and looking for brands that give them more than just a meal. That plays directly to the strength of TGI Fridays. We've always been at our best when we bring people together, create a little theatre and give guests a reason to stay longer, celebrate louder and come back again. Pakistan gives us an exciting new stage to do exactly that."

Pervaiz Iqbal Shahid, Founder and Group CEO, Meerab Properties, said:

"We are delighted to bring TGI Fridays back to Pakistan and to begin a new chapter for this iconic global brand in the country. Our ambition is to reintroduce the brand through an energized and well-capitalized platform, supported by strong operational leadership and a long-term commitment to responsible growth across Pakistan.

Our first flagship restaurant is targeted to open within the next 12 months at the prestigious Hyatt Regency Hotel complex in Lahore. This will provide an exceptional launch platform for the brand and establish the standard for the restaurants that follow.

Over the next decade, we look forward to developing TGI Fridays across Pakistan through a carefully considered combination of company-owned and approved sub-franchised restaurants. We are committed to protecting the strength of the brand, delivering an outstanding guest experience, and building a sustainable nationwide business together with the TGI Fridays team."

The agreement is TGI Fridays' second market signing this month, following the brand's first-ever entry into the Balkans, and builds on a series of international agreements over the past year spanning Kenya, the Maldives, Peru, Japan, Mexico, the Philippines, Greece, Cyprus and Spain. Together, these agreements have added close to 200 restaurants to TGI Fridays' global pipeline as the brand advances toward its 1-2-3 Strategic Vision of 1,000+ restaurants worldwide by 2030. The ambition is not about volume for its own sake but about selecting the right partners — experienced local operators who deeply understand the markets they are committed to developing.

At the heart of that growth is a deliberate franchise strategy: entering high-potential markets with partners who bring the local knowledge, capability and ambition to build TGI Fridays at scale. Meerab Hospitality is a strong example of that approach, combining deep market understanding with the hospitality expertise and ambition to build the brand for long-term success in Pakistan.

For more information: www.tgifridays.com/franchise/

About TGI Fridays™
Founded in 1965 as the world's first casual bar and grill, TGI Fridays is where the world goes to celebrate. Operating nearly 400 restaurants in almost 40 countries, Fridays brings people together through its craveable American classics, legendary cocktails and that unmistakable Fridays™ feeling - all brought to life by its rockstar teams. Whether it's full-service dining or bold-format convenience, TGI Fridays franchise-first approach, operational excellence, and brand power are built to scale. Franchisees are supported by global hubs in Dallas, Dubai and London, complemented by regional resources in select markets. Visit www.tgifridays.com for more information, join Fridays Rewards, and follow TGI Fridays™ on social media: Instagram @tgifridays, Tik Tok @tgifridays, Facebook TGI Fridays, and LinkedIn TGI Fridays.

About Meerab Hospitality
Headquartered in the United Arab Emirates, Meerab Properties is a diversified investment and operating company with investments and business interests across the UAE and Pakistan. The company develops long-term opportunities through direct ownership, strategic partnerships, and specialist operating platforms.

Through its hospitality platform, Meerab Hospitality Ventures, Meerab Properties is building a portfolio of international restaurant and hospitality brands in Pakistan, supported by experienced leadership, strong governance, and committed capital. Its strategy is focused on establishing sustainable businesses, developing local operating capabilities, and creating long-term value for its brand partners, customers, and stakeholders.

Media Contact:
TGIFridays@icrinc.com

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

TGI Fridays™ Signs Development Agreement to Fuel Pakistan Growth

TGI Fridays™ Signs Development Agreement to Fuel Pakistan Growth

  • 104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion
  • Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027
  • First-in-class PRS inhibitor being developed as a potential new therapeutic option for IPF

BARCELONA, Spain and SEOUL, South Korea, Sept. 24, 2026 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented a poster on the baseline characteristics of all 104 patients enrolled in the global Phase 2 clinical trial of its idiopathic pulmonary fibrosis (IPF) drug candidate 'Bersiporocin (DWN12088)' at the European Respiratory Society (ERS) Congress 2026, held on September 6 (local time) in Barcelona, Spain.

Idiopathic Pulmonary Fibrosis is a disease in which various inflammatory and fibrotic signals interact, leading to excessive production and accumulation of collagen. Bersiporocin, being developed by Daewoong Pharmaceutical, selectively inhibits prolyl-tRNA synthetase (PRS), thereby reducing excessive collagen production associated with fibrosis.

Bersiporocin has a differentiated mechanism of action that targets collagen synthesis downstream of multiple profibrotic signals through PRS inhibition. Based on this distinct mechanism, it is being evaluated both in patients receiving background antifibrotic therapy and in those not receiving such treatment.

This presentation analyzed the baseline clinical and functional characteristics of all IPF patients recruited in South Korea and the United States. Following the presentation of interim enrollment data at KATRDIC 2025, Daewoong Pharmaceutical presented baseline data from the fully enrolled study population for the first time at ERS 2026.

The analysis showed that of the total 104 patients, 55 (52.9%) were from South Korea and 49 (47.1%) from the US. A total of 71 patients (68.3%) were receiving background antifibrotic therapy, while 33 patients (31.7%) were not. Mean forced vital capacity (FVC) was approximately 77% predicted, while mean diffusing capacity of the lungs for carbon monoxide (DLCO) was approximately 51% predicted. Overall, baseline clinical and functional characteristics were generally similar between patients with and without background antifibrotic therapy.

The ongoing global Phase 2 study is a randomized, double-blind, placebo-controlled trial taking place in South Korea and the US. Patients receive either Bersiporocin or a placebo twice daily for 24 weeks, with concomitant use of pirfenidone or nintedanib permitted. The study design reflects real-world IPF treatment settings by including patients both with and without background antifibrotic therapy.

This baseline analysis provides important context for interpreting the Phase 2 efficacy and safety results. Daewoong Pharmaceutical plans to announce top-line Phase 2 results in the first half of 2027.

Meanwhile, Bersiporocin has received Orphan Drug Designation and Fast Track status from the US FDA, as well as Orphan Drug Designation from the European Medicines Agency (EMA), driving its global development forward.

Professor Moo Suk Park of the Department of Pulmonology at Severance Hospital, who participated in the study, said, "This study provides a comprehensive overview of the baseline characteristics of 104 IPF patients enrolled in South Korea and the US. As the study includes patients both with and without background antifibrotic therapy, these baseline data will provide important context for interpreting the efficacy and safety outcomes of Bersiporocin."

Seongsoo Park, CEO of Daewoong Pharmaceutical, stated, "Successfully completing enrollment for the global Phase 2 trial and sharing the full baseline patient profile at ERS 2026 marks a significant milestone in Bersiporocin's development. We will continue to advance the program toward top-line Phase 2 results in H1 2027 and use these findings to inform subsequent global development."

[Reference]

https://drive.google.com/file/d/1XSXImvc5mcgdoSozP_B4BnDlsTW7Pfz_/view 
Link to the poster: 'Baseline Clinical and Functional Spectrum of Idiopathic Pulmonary Fibrosis Patients in a Fully Enrolled Global Phase 2 Trial of the PRS Inhibitor Bersiporocin'

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026

Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026

Recommended Articles